Vir Biotechnology (VIR) Net Cash Flow (2018 - 2026)

Vir Biotechnology (VIR) has 9 years of Net Cash Flow data on file, last reported at $42.0 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 14.86% year-over-year to $42.0 million; the trailing twelve-month figure through Mar 2026 stood at -$85.0 million (down 145.3% YoY), and the FY2025 full-year result was -$77.6 million, down 235.23% from the prior year.
• Net Cash Flow retreated to $42.0 million in Q1 2026, from $61.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $690.9 million in Q2 2022 to a low of -$542.7 million in Q3 2022.
• A 5-year average of -$4.7 million and a median of -$52.8 million in 2024 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 452.44% in 2022, while the deepest fall reached 1816.04% in 2022.
• Tracing VIR's Net Cash Flow over 5 years: stood at -$116.0 million in 2022, then sank by 81.95% to -$211.1 million in 2023, then soared by 125.76% to $54.4 million in 2024, then increased by 13.7% to $61.8 million in 2025, then tumbled by 32.1% to $42.0 million in 2026.
• Business Quant data shows VIR's Net Cash Flow at $42.0 million in Q1 2026, $61.8 million in Q4 2025, and -$127.0 million in Q3 2025.